After just a week on the job, Stada Arzneimittel AG's newly appointed CEO and CFO have accepted a fresh takeover bid from equity groups Bain Capital and Cinven, valuing the company at $4.12bn or €66.25 per share – slightly higher than the duo's previous offer that fell through in late June.
Bain and Cinven had previously offered €66 per share to acquire Stada, a German generic drug maker, but this offer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?